Sandoz Obtains Positive CHMP Opinion For Multiple Sclerosis Biosimilar Natalizumab
24/7 07:57
(RTTNews) - Sandoz said Monday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has adopted a positive opinion for marketing authorization for first-of-a-kind biosimilar natalizumab developed by Polpharma Biologics....